Johnson & Johnson Press Releases https://www.investor.jnj.com/generated by Q4Sat, 25 Jul 2026 13:44:37 -0400Copyright Q4 Inc. All rights reserved.TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomabe1f7676-22ff-4e88-995d-98bbfd340257https://www.investor.jnj.com/investor-news/news-details/2026/TECVAYLI--TALVEY-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-risk-of-death-by-62-in-earlier-line-relapsedrefractory-multiple-myeloma/default.aspxThu, 23 Jul 2026 08:30:00 -0400Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System822d0afe-7e21-42ab-b5b4-4a49ae2799fdhttps://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Receives-FDA-Market-Authorization-in-the-U-S--for-its-OTTAVA-Robotic-Surgical-System/default.aspxWed, 22 Jul 2026 07:00:00 -0400Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award438d65d6-4ca2-4743-ace9-afd91a6d5901https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Announces-Collaboration-with-TIME-to-Introduce-New-Healthcare-Champion-of-the-Year-Award/default.aspxThu, 16 Jul 2026 08:11:00 -0400Johnson & Johnson Announces Quarterly Dividend for Third Quarter 20261a2381c3-0cb1-4548-a763-415f63e15405https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Announces-Quarterly-Dividend-for-Third-Quarter-2026/default.aspxWed, 15 Jul 2026 06:25:00 -0400Johnson & Johnson reports Q2 2026 results, raises 2026 outlookd8efd341-8856-4852-8d85-6db4740d69abhttps://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspxWed, 15 Jul 2026 06:20:00 -0400Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform2ec4a5cc-4a6d-4fab-9d39-69bbd0a486dahttps://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Announces-FDA-Approval-for-the-Dual-Energy-THERMOCOOL-SMARTTOUCH-SF-Platform/default.aspxWed, 08 Jul 2026 07:45:00 -0400DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer 4ad668f8-13f8-40f7-94be-2405c34e3e98https://www.investor.jnj.com/investor-news/news-details/2026/DePuy-Synthes-Appoints-Christina-Zamarro-as-Chief-Financial-Officer--2026-Lg0IIPIzI9/default.aspxMon, 29 Jun 2026 16:30:00 -0400Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravisb4c56991-d9fe-4c82-b615-f6e57c813198https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-presents-new-IMAAVY-nipocalimab-aahu-data-at-European-Academy-of-Neurology-EAN-2026-Congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis/default.aspxFri, 26 Jun 2026 12:35:00 -0400CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myelomaf0a59c1f-c4a8-4063-898f-4384ac1805f9https://www.investor.jnj.com/investor-news/news-details/2026/CHMP-recommendation-advances-Johnson--Johnsons-TECVAYLI-teclistamab-plus-daratumumab-as-a-potential-standard-of-care-for-relapsedrefractory-multiple-myeloma-2026-81_gOgYIQp/default.aspxFri, 26 Jun 2026 08:00:00 -0400Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Floridadac552e1-d0a2-4818-ae5f-8f8701b55c66https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Invests-more-than-1-Billion-to-Strengthen-U-S--Vision-Manufacturing-in-Jacksonville-Florida/default.aspxMon, 15 Jun 2026 06:00:00 -0400